PODDInsulet Corporation

Insulet has built a real but bounded competitive advantage around its tubeless Omnipod platform. The franchise benefits from strong patient convenience, recurring consumables, clinician familiarity, and a credible brand in automated insulin delivery, while the switching burden for users is meaningful. Its moat is reinforced by proprietary technology and patents, but the diabetes-device market remains competitive and not structurally closed; large incumbents and well-funded rivals continue to pressure pricing and innovation. Scale in pod manufacturing also helps margins, though it is not enough to create an unassailable cost position. The overall moat is therefore durable but narrower than a true platform monopoly, with momentum improving as Omnipod expands globally and into new patient segments.